COVID-19 IgG Formation in Physicians at ALGH and Their Household Members
NCT04540484 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 507
Last updated 2024-10-03
Summary
This study is a community hospital-based study that will enhance information being obtained in similar studies taking place in France, Denmark, and China. These studies are designed to assess risk of healthcare workers during outbreaks of Coronavirus 2019 (COVID-19) also known as sudden acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). This will be a prospective, single-center observational study involving human subjects. IgG (Immunoglobulin G) antibody will be tested in the serum of physicians working at Advocate Lutheran General Hospital (ALGH). IgG antibodies are the antibodies that form in response to viral or bacterial infections and typically reflect protection against said infection. To date, there have been no studies confirming that IgG antibody formation confers immunity, but studies are ongoing. Furthermore, data is lacking showing conclusive persistence of (possibly protective) antibodies over time. Attending physicians on the medical staff, fellow physicians, and house staff residents who worked at ALGH from March 1st, 2020 and on, will be eligible for the study. Testing will involve a venipuncture to obtain approximately 3mL of blood to be sent to ACL Laboratories for SARS-CoV-2 IgG testing. For physician subjects, this will be performed on four separate occasions, once at the onset of the study, a second test 3 months after the first test, a third test 6 months from the time of the first test, and a fourth and final test 12 months after the initial test. Two household members (defined below), one-time testing will occur within 2 weeks of the physician subject testing positive. All testing will be performed in a two-week window. All physician subjects will be tested at a centralized site that is only serving these subjects, by appointment. We will be offloading testing for household members to one localized commercial ACL site on the ALGH campus at the Center for Advanced Care. The household member testing will be extended to an additional two-week period after the two week window in which physicians are tested for a total of four weeks maximum. One-time testing for IgG antibodies to COVID-19 will be offered to a maximum of two household members, as defined as, any person over the age of 18 years old who has lived at home with the physician, who has tested positive for IgG antibodies, for at least 2 weeks in total duration since March 1st, 2020. The physician will be permitted to choose who gets tested, and the chosen adult subject will provide their independent consent to be tested.
Conditions
- Covid19
- SARS-CoV Infection
- Communicable Disease
Interventions
- OTHER
-
Screening
Blood test screening for covid
Sponsors & Collaborators
-
Wake Forest University Health Sciences
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-08-26
- Primary Completion
- 2021-10-14
- Completion
- 2021-12-14
Countries
- United States
Study Locations
More Related Trials
-
Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms
NCT05484700 ·Status: UNKNOWN
-
COVID-19 IgG Antibodies in the Serum of Recovered Patients
NCT04470414 ·Status: UNKNOWN
-
Professional's Health in Epidemiological Crisis Covid-19
NCT04885478 ·Status: UNKNOWN
-
Seroprevalence of MERS-CoV IgG in Healthcare Workers
NCT02497885 ·Status: COMPLETED
-
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
NCT04383587 ·Status: COMPLETED ·Phase: NA
-
Neutralizing Antibody Level After COVID-19 Vaccination
NCT05083026 ·Status: RECRUITING
-
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
NCT04543006 ·Status: UNKNOWN ·Phase: NA
-
Monitoring the IgG/IgM Antibodies in COVID-19 Patients
NCT04810117 ·Status: COMPLETED
-
SARS-CoV-2 IgG and IgM Serologic Assays
NCT04562246 ·Status: COMPLETED
-
Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays
NCT04562285 ·Status: COMPLETED
-
Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients
NCT04410471 ·Status: UNKNOWN
-
Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients
NCT04817553 ·Status: COMPLETED
-
Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants
NCT05858502 ·Status: RECRUITING ·Phase: NA
-
Gene Polymorphism of IL17 and IL 23
NCT04948515 ·Status: COMPLETED
-
Seroconversion in COVID-19 Recovered Population
NCT04558385 ·Status: COMPLETED
-
A Cross-sectional Study on the Association of Peptidoglycan Fragments Derived From Gut Microbiota With Alcohol Liver Disease
NCT07284862 ·Status: COMPLETED
-
Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection
NCT05242159 ·Status: UNKNOWN
-
Study of Lymphopenia as a Specific Biomarker or Prognostic Risk Factor for Disease Severity in Elderly Patients With COVID-19
NCT04800731 ·Status: COMPLETED
-
COVID-19 Antibody and Reinfection Study
NCT05365750 ·Status: COMPLETED
-
Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive
NCT04605952 ·Status: COMPLETED
-
Characterization of the Immunometabolic Signature in Long COVID-19.
NCT05758480 ·Status: COMPLETED ·Phase: NA
-
Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?
NCT04469634 ·Status: COMPLETED ·Phase: NA
-
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination
NCT04880174 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19
NCT04367714 ·Status: UNKNOWN
-
Study of Dengue in Patients With Autoimmune Diseases During the Epidemics of 2020 and 2021 in Reunion Island
NCT05852977 ·Status: NOT_YET_RECRUITING